ArticleJournal of feline medicine and surgery2021
The Feline Cardiomyopathies: 1. General concepts.
Article in Journal of feline medicine and surgery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Cardiovascular biomarkers in feline hypertrophic cardiomyopathy phenotype: evidence from the last decade.Veterinary research communications · 2026Pooled it
- Reduced Plasma Cardiac Myosin-Binding Protein-C Concentrations in Cats with Hypertrophic Cardiomyopathy: Evidence from Chronic, Treated Disease.Animals : an open access journal from MDPI · 2026Article
- Long-Term Control of Refractory Cardiogenic Pleural Effusion in a Cat Treated with Sacubitril/Valsartan and Hydrochlorothiazide: A Case Report.Animals : an open access journal from MDPI · 2026Article
- Diagnostic Ophthalmology.The Canadian veterinary journal = La revue veterinaire canadienne · 2026Article
- In Silico Discovery of mTOR Inhibitors as Potential Therapeutics for Feline Hypertrophic Cardiomyopathy.Journal of molecular modeling · 2026Article
- Early activation of Virchow's triad in feline hypertrophic cardiomyopathy: beyond spontaneous echo contrast and insights into translational thromboembolism.Frontiers in veterinary science · 2026Review
- Acute Effect of Furosemide on Left Atrium Size in Cats with Acute Left-Sided Congestive Heart Failure.Animals : an open access journal from MDPI · 2025Article
- Evidence for chronic inflammation in cats with cardiomyopathies.Journal of feline medicine and surgery · 2025Article
- Experimental Models of Hypertrophic Cardiomyopathy: A Systematic Review.JACC. Basic to translational science · 2025Review
- Clinical-Diagnostic and Therapeutic Advances in Feline Hypertrophic Cardiomyopathy.Veterinary sciences · 2025Review
- Myocardial expression of connexin 43 in cats with hypertrophic and restrictive cardiomyopathy phenotype.Open veterinary journal · 2025Article
- The Pathological and Histopathological Findings in Cats with Clinically Recognised Hypertrophic Cardiomyopathy Are Related to the Severity of Clinical Signs and Disease Duration.Animals : an open access journal from MDPI · 2025Article
- Linking clinical and imaging diagnostic assessments of the feline hypertrophic cardiomyopathy phenotype.Frontiers in veterinary science · 2025Review
- Arrhythmias across the tree of life: comparative insights for human electrophysiology.Frontiers in cardiovascular medicine · 2025Review
- CRISPR/Cas9-mediated CH2 deletion of Fel d1 triggers transcriptomic reprogramming and disease-associated pathways in feline cells.Frontiers in cell and developmental biology · 2025Article
- Feline hypertrophic cardiomyopathy: Does the microRNA-mRNA regulatory network contribute to heart sarcomeric protein remodelling?International journal of experimental pathology · 2024Article
- Parameters related to diagnosing hypertrophic cardiomyopathy in cats.Open veterinary journal · 2024Article
- Case report: Diffuse large B-cell lymphoma presenting as congestive heart failure in a cat.Frontiers in veterinary science · 2024Article
- Classification of feline hypertrophic cardiomyopathy-associated gene variants according to the American College of Medical Genetics and Genomics guidelines.Frontiers in veterinary science · 2024Article
- Recasting the gold standard - part I of II: delineating healthcare options across a continuum of care.Journal of feline medicine and surgery · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
practical relevanceThe feline cardiomyopathies are the most prevalent type of heart disease in adult domestic cats. Several forms have been identified (see Parts 2 and 3), with hypertrophic cardiomyopathy (HCM) being the most common. Clinically the cardiomyopathies are often indistinguishable. Cats with subclinical cardiomyopathy may or may not have characteristic physical examination findings (eg, heart murmur, gallop sound), or radiographic cardiomegaly. Cats with severe disease may develop signs of heart failure (eg, dyspnea, tachypnea) or systemic arterial thromboembolism (ATE; eg, pain and paralysis). Sudden death is possible. Treatment usually does not alter the progression from subclinical to clinical disease and often the treatment approach, once clinical signs are apparent, is the same regardless of the type of cardiomyopathy. However, differentiating cardiomyopathy from normal variation may be important prognostically. PATIENT GROUP: Domestic cats of any age from 3 months upward, of either sex and of any breed, can be affected. Mixed-breed cats are most commonly affected but certain breeds are disproportionately prone to developing HCM. DIAGNOSTICS: Subclinical feline cardiomyopathies may be suspected based on physical examination findings, thoracic radiographs and cardiac biomarker results but often the disease is clinically silent. The definitive clinical confirmatory test is echocardiography. Left heart failure (pulmonary edema and/or pleural effusion) is most commonly diagnosed radiographically, but point-of-care ultrasound and amino terminal pro-B-type natriuretic peptide (NT-proBNP) biomarker testing can also be useful, especially when the stress of taking radiographs is best avoided. KEY
findingsKnowledge of pathophysiological mechanisms helps the practitioner identify the feline cardiomyopathies and understand how these diseases progress and how they manifest clinically (heart failure, ATE). Existing diagnostic tests have strengths and limitations, and being aware of these can help a practitioner deliver optimal recommendations regarding referral.
conclusionsSeveral types of feline cardiomyopathies exist in both subclinical (mild to severe disease) and clinical (severe disease) phases. Heart failure and ATE are the most common clinical manifestations of severe cardiomyopathy and are therapeutic targets regardless of the type of cardiomyopathy. The long-term prognosis is often guarded or poor once overt clinical manifestations are present. AREAS OF UNCERTAINTY: Some cats with presumed cardiomyopathy do not have echocardiographic features that fit the classic cardiomyopathies (cardiomyopathy - nonspecific phenotype). Although no definitive treatment is usually available, understanding how cardiomyopathies evolve remains worthy of investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.